Literature DB >> 19750747

Effects of angiotensin-converting enzyme inhibition on plasma aldosterone concentration, plasma renin activity, and blood pressure in spontaneously hypertensive cats with chronic renal disease.

Jennifer L Steele1, Rosemary A Henik, Rebecca L Stepien.   

Abstract

Hypertension is commonly associated with chronic renal disease in cats, and inappropriate activation of the renin-angiotensin-aldosterone system (RAAS) may contribute to the hypertensive state. Angiotensin-converting enzyme (ACE) inhibitors are commonly administered when hypertension is present to decrease plasma concentrations of angiotensin II and aldosterone, which cause vasoconstriction and sodium and water retention, respectively. The study reported here was conducted over a 6-month period to assess the effects of two commonly prescribed ACE inhibitors, enalapril and benazepril, on the activity of the RAAS and blood pressure in 16 spontaneously hypertensive cats with chronic renal disease. Plasma aldosterone and plasma renin activity were not significantly affected by ACE inhibitors in hypertensive cats, and systolic blood pressure did not decrease below 170 mm Hg with ACE inhibitor monotherapy in 14 of 16 cats. These results suggest that continued activation of the RAAS is present in hypertensive cats despite treatment with an ACE inhibitor, and ACE inhibitors should not be used as first-line antihypertensive treatment in hypertensive cats.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 19750747

Source DB:  PubMed          Journal:  Vet Ther        ISSN: 1528-3593


  7 in total

Review 1.  The renin-angiotensin-aldosterone system and its suppression.

Authors:  Marisa K Ames; Clarke E Atkins; Bertram Pitt
Journal:  J Vet Intern Med       Date:  2019-02-26       Impact factor: 3.333

2.  Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double-blind, placebo-controlled, randomized clinical trial.

Authors:  Amanda E Coleman; Scott A Brown; Anne M Traas; Lawrence Bryson; Tanja Zimmering; Alicia Zimmerman
Journal:  J Vet Intern Med       Date:  2019-03-09       Impact factor: 3.333

3.  Efficacy of long-term oral telmisartan treatment in cats with hypertension: Results of a prospective European clinical trial.

Authors:  Tony M Glaus; Jonathan Elliott; Esther Herberich; Tanja Zimmering; Balazs Albrecht
Journal:  J Vet Intern Med       Date:  2018-12-18       Impact factor: 3.333

4.  Characterization of the intrarenal renin-angiotensin system in cats with naturally occurring chronic kidney disease.

Authors:  Bianca N Lourenço; Amanda E Coleman; Roy D Berghaus; Jaime L Tarigo; Chad W Schmiedt; Scott A Brown
Journal:  J Vet Intern Med       Date:  2022-01-19       Impact factor: 3.333

5.  Plasma renin activity and aldosterone concentrations in hypertensive cats with and without azotemia and in response to treatment with amlodipine besylate.

Authors:  R E Jepson; H M Syme; J Elliott
Journal:  J Vet Intern Med       Date:  2013-11-13       Impact factor: 3.333

6.  Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone:creatinine, after pharmacologic provocation) and the response to ACE inhibition.

Authors:  Marisa K Ames; Clarke E Atkins; Andrea C Lantis; James zum Brunnen
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2016-03-23       Impact factor: 1.636

7.  ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats.

Authors:  Mark J Acierno; Scott Brown; Amanda E Coleman; Rosanne E Jepson; Mark Papich; Rebecca L Stepien; Harriet M Syme
Journal:  J Vet Intern Med       Date:  2018-10-24       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.